Skip to main content

Table 2 Overall VFQ-25 subscale scores (all indications) as well as stratified data of treatment-naïve and pre-treated patients

From: Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study

  Baseline score [95 % confidence interval]
VFQ-25 subscale All (N = 4844)a Naïve (N = 3414)a Pre-treated (N = 741)a
General health 45.3 [44.7; 45.8] 45.9 [45.3; 46.6] 43.8 [42.4; 45.3]
General vision 59.5 [59.0; 60.0] 59.7 [59.1; 60.3] 58.8 [57.4; 60.1]
Ocular pain 86.5 [85.9; 87.0] 87.2 [86.6; 87.8] 85.8 [84.4; 87.1]
Near vision 67.0 [66.2; 67.7] 67.8 [67.0; 68.7] 64.1 [62.2; 66.1]
Distance vision 70.7 [69.9; 71.4] 71.9 [71.0; 72.7] 66.2 [64.2; 68.3]
Social function (vision specific) 83.8 [83.1; 84.5] 84.9 [84.1; 85.7] 81.4 [79.5; 83.2]
Mental health (vision specific) 67.9 [67.3; 68.6] 68.8 [68.0; 69.5] 65.1 [63.3; 67.0]
Role limitations (vision specific) 69.2 [68.4; 70.1] 70.5 [69.4; 71.5] 64.6 [62.2; 67.0]
Dependency (vision specific) 82.1 [81.3; 82.9] 83.3 [82.4; 84.2] 79.8 [77.6; 81.9]
Driving 59.6 [58.3; 60.9] 60.0 [58.5; 61.6] 54.1 [50.5; 57.6]
Colour vision 89.6 [89.0; 90.2] 90.3 [89.6; 91.0] 89.1 [87.5; 90.6]
Peripheral vision 74.9 [74.1; 75.6] 76.2 [75.3; 77.1] 71.2 [69.2; 73.2]
  1. aMissing data for <3 % in subscale scores; except for driving, which is only reported for those subjects who reported to currently drive or to have given up driving mainly due to eyesight